COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
Denosumab Use in Myeloma Soars for No Obvious Reason More expensive than competitor without being better, so why does it now have nearly half the market? Dec 12, 2019
Serum Immune Markers May Predict Conversion From MGUS to Myeloma Results could support annual blood tests and risk assessment for those with MGUS and its subtype, light-chain MGUS Jul 19, 2019
Combination Regimen Extends PFS in Myeloma Large benefit but relevance of comparator questioned Dec 04, 2018
NCCN Refines MM Treatment Guidelines 'An attempt to help the clinician make better decisions,' expert says Mar 25, 2018
Longer PFS in Myeloma with Add-On Daratumumab Anti-CD38 drug boosts response to VMP regimen Dec 12, 2017
Novel Agent Shows Antitumor Activity in TRK-Fusion Cancers Tumor genetics define treatment approach in early-stage trials Jun 04, 2017
MSK Cancer Alliance: Mainly About Medicine Bi-directional relationship strengthens regional cancer care Mar 11, 2017
Pembrolizumab Plus Lenalidomide Gets Response in MM Combo shows signs of benefit in relapsed/refractory myeloma Jun 10, 2016
Novel Agent Promising in Pretreated Myeloma Phase II trial shows 18-month median survival with isatuximab Jun 09, 2016
Combo Boosts PFS in Tough-to-Treat Myeloma Recurrent or relapsed disease susceptible to daratumumab-bortezomib-dexamethasone Jun 07, 2016
Revlimid Maintenance Benefits Multiple Myeloma Prolonged overall survival in patients post-autologous stem cell transplant Jun 06, 2016
Transplant Remains King for New Myeloma Significant improvement in PFS versus systemic treatment May 19, 2016
One Proteasome Inhibitor Tops Another in Relapsed Myeloma Progression-free survival doubled with carfilzomib versus bortezomib Jun 15, 2015
PFS Rises in Progressive Myeloma with Targeted Biologic Adding elotuzumab boosts median progression-free survival by almost 5 months. Jun 12, 2015
Part 2: Oncologists Weigh In on PBS Cancer Documentary Six specialists share their impressions of Ken Burns' cancer opus. Apr 13, 2015
HDAC Inhibitor OK'd for Multiple Myeloma Panobinostat targets histone deacetylases; first of its kind to win approval in myeloma. Feb 23, 2015
ASCO: Myeloma Study Results Inconclusive CHICAGO -- A trial comparing two immunomodulatory regimens for myeloma failed to demonstrate noninferiority for the newer drug. Jun 06, 2014
ASCO: Combo Extends PFS in Relapsed Myeloma CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed. Jun 05, 2014
OncoBriefs: Myeloma Tx, In Situ Melanoma Superficial melanoma conferred a risk of recurrent invasive melanoma similar to that of primary invasive melanoma, Australian investigators reported. The study is one of several oncology-related news items summarized in OncoBriefs. Mar 23, 2014
Infection High in Myeloma, with High Mortality ATLANTA -- More than a fifth of patients with multiple myeloma died of infection within a year of diagnosis, Swedish investigators reported here. Dec 14, 2012
Oral Azacitidine Safe, Effective in Low-Risk MDS ATLANTA -- Oral azacitidine (Vidaza) given for up to 21 days per 4-week cycle for myelodysplastic syndrome appeared safe and effective in patients with lower-risk disease, a researcher said here. Dec 14, 2012
FDA: Revlimid Linked to Second Cancers Treatment of multiple myeloma with lenalidomide (Revlimid) as maintenance therapy is associated with an increased risk of second primary cancers, the FDA warned. May 08, 2012
Clinical Notes: Beware the Seat Heater debuts a new regular feature, a roundup of clinical news you might otherwise have missed. This week we led with a report that heated car seats can leave passengers with "toasted skin syndrome." Feb 26, 2012
Withdrawal Tough With Novel Drug for Myelofibrosis The novel Janus kinase (JAK) inhibitor ruxolitinib relieves myelofibrosis symptoms, but withdrawal from the drug can be severe, researchers warned. Oct 13, 2011
Medicare to Cover More PET Scans for Cancer Diagnosis BALTIMORE -- The Centers for Medicare and Medicaid Services announced expanded coverage of PET scans for Medicare patients suspected of having most cancers. Apr 07, 2009
